Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis
- 12 December 2006
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 103 (50), 19057-19062
- https://doi.org/10.1073/pnas.0607242103
Abstract
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. Although the cause of MS is still uncertain, many findings point toward an ongoing autoimmune response to myelin antigens. Because of its location on the outer surface of the myelin sheath and its pathogenicity in the experimental autoimmune encephalomyelitis model, myelin oligodendrocyte glycoprotein (MOG) is one of the potential disease-causing self antigens in MS. However, the role of MOG in the pathogenesis of MS has remained controversial. In this study we addressed the occurrence of autoantibodies to native MOG and its implication for demyelination and axonal loss in MS. We applied a high-sensitivity bioassay, which allowed detecting autoantibodies that bind to the extracellular part of native MOG. Antibodies, mostly IgG, were found in sera that bound with high affinity to strictly conformational epitopes of the extracellular domain of MOG. IgG but not IgM antibody titers to native MOG were significantly higher in MS patients compared with different control groups with the highest prevalence in primary progressive MS patients. Serum autoantibodies to native MOG induced death of MOG-expressing target cells in vitro. Serum from MS patients with high anti-MOG antibody titers stained white matter myelin in rat brain and enhanced demyelination and axonal damage when transferred to autoimmune encephalomyelitis animals. Overall these findings suggest a pathogenic antibody response to native MOG in a subgroup of MS patients.Keywords
This publication has 38 references indexed in Scilit:
- Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjectsNeurology, 2004
- Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis after a First Demyelinating EventNew England Journal of Medicine, 2003
- Unravelling the pathogenesis of myasthenia gravisNature Reviews Immunology, 2002
- New concepts in the immunopathogenesis of multiple sclerosisNature Reviews Neuroscience, 2002
- T‐ and B‐cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosisGlia, 2001
- Multiple sclerosis: a two-stage diseaseNature Immunology, 2001
- Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination.Journal of Clinical Immunology, 2001
- Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative studyBrain, 1999
- A novel myelin-associated glycoprotein defined by a mouse monoclonal antibodyJournal of Neuroimmunology, 1984
- Characterization of an established human malignant glioma cell line: LN-18Acta Neuropathologica, 1981